But the gap between the share of Americans who have tried a GLP-1 drug (about 12 percent as of last year) and the share who are obese (about 37 percent) suggests there is a sizable percentage of people who could benefit from these drugs but have not been taking them
This represents the single largest expansion of semaglutide access in US history and is expected to significantly increase prescription volumes in the second half of 2026
Carnitine Shuttle and Fatty Acid -Oxidation Carnitine plays a vital role in fatty acid -oxidation and energy metabolism
Results Overall, 2.9% [2.43.4%] approximately 1.6 million adultsreported using a GLP-1 or GLP-1/GIP medication to support weight loss in the past year, with 1.7% [1.42.1%] (~ 910,000 adults) using them exclusively for this purpose
Use of this product constitutes acceptance of the Modified Aminos Terms and Conditions
As a result, specialty medications (including GLP-1s) may be designated as either medical benefit drugs or pharmacy benefit drugs based on their mode of delivery and approved uses ( [10] )